XINT Stock | | | SEK 0.32 0.01 3.23% |
Executive
Mr. Thomas Areschoug was Business Development Manager at Xintela AB since March 21, 2017. Thomas Areschoug has recently worked with business development at Invest in Skane, where he built up a broad network of pharmaceutical companies and investors. He marketed companies in Southern Sweden and facilitated contacts and partnerships with international players. Thomas Areschoug also has a broad background in biomedical research with a focus on microbiology and immunology. In addition, he was active in biotechnology companies and worked with business development, project management and financing. He also has experience of Board work. since 2017.
Age | 51 |
Tenure | 7 years |
Phone | 46 4 62 75 65 00 |
Web | https://www.xintela.se |
Xintela AB Management Efficiency
The company has return on total asset
(ROA) of
(1.1374) % which means that it has lost $1.1374 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(4.6888) %, meaning that it generated substantial loss on money invested by shareholders. Xintela AB's management efficiency ratios could be used to measure how well Xintela AB manages its routine affairs as well as how well it operates its assets and liabilities.
Xintela AB , a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company was founded in 2009 and is based in Lund, Sweden. Xintela AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 13 people. Xintela AB (XINT) is traded on Stockholm Exchange in Sweden and employs 16 people.
Management Performance
Xintela AB Leadership Team
Elected by the shareholders, the Xintela AB's board of directors comprises two types of representatives: Xintela AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xintela. The board's role is to monitor Xintela AB's management team and ensure that shareholders' interests are well served. Xintela AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xintela AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
Xintela Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xintela AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Xintela Stock Analysis
When running Xintela AB's price analysis, check to
measure Xintela AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xintela AB is operating at the current time. Most of Xintela AB's value examination focuses on studying past and present price action to
predict the probability of Xintela AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xintela AB's price. Additionally, you may evaluate how the addition of Xintela AB to your portfolios can decrease your overall portfolio volatility.